BIOINVENT INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.15 SEK | +1.62% |
|
+6.12% | +32.65% |
Presenter SpeechMartin Welschof (Executives)Yes. Welcome, everybody, to our year-end report, a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
2024-05-03
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
25.15
SEK
Average target price
83
SEK
Spread / Average Target
+230.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.65% | 151M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BINV Stock
- News BioInvent International AB
- Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024
